- Home
- MBRX vs ADIL Comparison
MBRX vs ADIL Comparison
Compare MBRX & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- ADIL
- Stock Information
- Founded
- MBRX 2015
- ADIL 2010
- Country
- MBRX United States
- ADIL United States
- Employees
- MBRX N/A
- ADIL N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- ADIL Health Care
- Exchange
- MBRX Nasdaq
- ADIL Nasdaq
- Market Cap
- MBRX 4.4M
- ADIL 4.3M
- IPO Year
- MBRX 2016
- ADIL 2018
- Fundamental
- Price
- MBRX $0.84
- ADIL $0.64
- Analyst Decision
- MBRX Strong Buy
- ADIL Strong Buy
- Analyst Count
- MBRX 3
- ADIL 1
- Target Price
- MBRX $17.33
- ADIL $8.00
- AVG Volume (30 Days)
- MBRX 651.2K
- ADIL 72.4K
- Earning Date
- MBRX 05-09-2025
- ADIL 05-13-2025
- Dividend Yield
- MBRX N/A
- ADIL N/A
- EPS Growth
- MBRX N/A
- ADIL N/A
- EPS
- MBRX N/A
- ADIL N/A
- Revenue
- MBRX N/A
- ADIL N/A
- Revenue This Year
- MBRX N/A
- ADIL N/A
- Revenue Next Year
- MBRX N/A
- ADIL N/A
- P/E Ratio
- MBRX N/A
- ADIL N/A
- Revenue Growth
- MBRX N/A
- ADIL N/A
- 52 Week Low
- MBRX $0.40
- ADIL $0.61
- 52 Week High
- MBRX $5.91
- ADIL $3.10
- Technical
- Relative Strength Index (RSI)
- MBRX 36.19
- ADIL 39.91
- Support Level
- MBRX $0.92
- ADIL $0.67
- Resistance Level
- MBRX $1.04
- ADIL $0.72
- Average True Range (ATR)
- MBRX 0.10
- ADIL 0.05
- MACD
- MBRX -0.01
- ADIL 0.00
- Stochastic Oscillator
- MBRX 3.98
- ADIL 13.42
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.